On December 14, 2023, Avalo Therapeutics, Inc. closed the transaction. The company has now issued 3,627,797 Series Seed Preferred Stock and issued warrants to purchase 1,813,896 shares of common stock at a purchase price of $0.64904 per share for the gross proceeds of $2,354,585.36488. The company has paid issuance expenses of $30,000 and net proceeds is $2,324,585.36488.